Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Blood (2023) 141 (17): 2114–2126.

https://doi.org/10.1182/blood.2022017333

Published: 2023

Includes: Supplemental data

Journal Articles

A Novel Aggressive NK Cell Leukemia Cell Line and Mouse Model for Evaluation of Therapeutic Candidates

Xiaoxian Zhao, Caroline Astbury, Feng Lin, Darren C. Phillips, Eric D. Hsi

Blood (2021) 138 (Supplement 1): 1198.

https://doi.org/10.1182/blood-2021-146645

Published: 2021

Journal Articles

The Combinatorial Activity of Eftozanermin (ABBV-621), a Novel and Potent TRAIL Receptor Agonist Fusion Protein, in Pre-Clinical Models of Hematologic Malignancies

Morey L Smith, MS, Sha Jin, MS, Dong Chen, MS, Haichao Zhang, PhD, Jason Huska, PhD, Deborah Widomski, Vicky Bontcheva, Greg Buchanan, PhD, Susan Morgan-Lappe, PhD, Darren C. Phillips, PhD, Stephen K Tahir, PhD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-136155

Published: 2020

Journal Articles

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

Brianna N Smith, MD MS, Dan Cojocari, PhD BSc, Julie J Purkal, MA, Maria Arrate, MSc, Haley E. Ramsey, PhDMSc, Joel D. Leverson, PhD, Erwin Boghaert, MS, MD, Darren C. Phillips, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1380.

https://doi.org/10.1182/blood-2019-123068

Published: 2019

Journal Articles

5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis

Dan Cojocari, PhD BSc, Sha Jin, MS, Julie J Purkal, MA, Relja Popovic, PhD, Nari N Talaty, PhD, Yu Xiao, MS, Larry R Solomon, PhD, Erwin Boghaert, MS, MD, Joel D. Leverson, PhD, Darren C. Phillips, PhD

Blood (2018) 132 (Supplement 1): 2644.

https://doi.org/10.1182/blood-2018-99-111985

Published: 2018

Journal Articles

Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models

Severine Cathelin, PhD, David Sharon, PhD, Amit Subedi, PhD, Dan Cojocari, PhD BSc, Darren C. Phillips, PhD, Joel D. Leverson, PhD, Kyle MacBeth, PhD, Brandon Nicolay, Rohini Narayanaswamy, Sebastien Ronseaux, Guowen Liu, PhD, Steven M Chan, MD PhD

Blood (2018) 132 (Supplement 1): 562.

https://doi.org/10.1182/blood-2018-99-119688

Published: 2018

Journal Articles

Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors

Stephen Kenneth Tahir, PhD, Morey L Smith, MS, Larry R Solomon, PhD, Haichao Zhang, PhD, John C Xue, MD, Yu Xiao, MS, Dong Cheng, MS, Greg Buchanan, PhD, Susan Morgan-Lappe, PhD, Darren C. Phillips, PhD

Blood (2017) 130 (Supplement 1): 2812.

https://doi.org/10.1182/blood.V130.Suppl_1.2812.2812

Published: 2017

Journal Articles

Inhibition of Cyclin Dependent Kinase 9 Synergistically Enhanced Venetoclax Activity in Mantle Cell Lymphoma Cells

Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Ruoying Chen, PhD, Lisa Durkin, Andrew J. Souers, PhD, Darren C. Phillips, PhD, Eric D. Hsi, MD

Blood (2016) 128 (22): 1593.

https://doi.org/10.1182/blood.V128.22.1593.1593

Published: 2016

Journal Articles

Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

Lina Han, MD PhD, Qi Zhang, MD PhD, Ce Shi, MD PhD, Antonio Cavazos, MS, Vivian Ruvolo, MS, Joel Leverson, Dail Monique, PhD, Darren C. Phillips, PhD, Jun Chen, MD PhD, Sha S Jin, Rodrigo Omar Jacamo, PhD, Naval Daver, MD, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Deepak Sampath, PhD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 97.

https://doi.org/10.1182/blood.V128.22.97.97

Published: 2016

Journal Articles

The Synergistic Effect of Venetoclax Combined with a CDK9 Inhibitor in Primary Diffuse Large B Cell Lymphoma and Follicular Lymphoma Cells

Xiaoxian Zhao, PhD, Darren C. Phillips, PhD, Andrew J. Souers, PhD, Juraj Bodo, PhD, Paul Tapang, Daniel H Albert, PhD, Lisa Durkin, Eric D. Hsi, MD

Blood (2015) 126 (23): 2746.

https://doi.org/10.1182/blood.V126.23.2746.2746

Published: 2015

Journal Articles

Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models

Lina Han, PhD, Qi Zhang, Ce Shi, PhD, Joel Leverson, PhD, Monique Dail, Darren C. Phillips, PhD, Jun Chen, MDPhD, Sha S Jin, Rodrigo Omar Jacamo, PhD, Naval Daver, MD, Elias J Jabbour, MD, Hagop M Kantarjian, MD, Michael Andreeff, MD PhD, Deepak Sampath, PhD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 2544.

https://doi.org/10.1182/blood.V126.23.2544.2544

Published: 2015

Journal Articles

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

Jun Chen, MDPhD, Sha Jin, MS, Paul Tapang, Stephen K Tahir, PhD, Morey Smith, John Xue, Haichao Zhang, PhD, Wenqing Gao, PhD, Yunsong Tong, PhD, Richard Clark, Justin L. Ricker, MD PhD, Thomas D Penning, PhD, Daniel H Albert, PhD, Darren C Phillips, PhD, Andrew J Souers, PhD, Joel D. Leverson, PhD

Blood (2014) 124 (21): 2161.

https://doi.org/10.1182/blood.V124.21.2161.2161

Published: 2014

Journal Articles

The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study

A Carroll, C Civin, N Schneider, G Dahl, A Pappo, P Bowman, A Emami, S Gross, C Alvarado, C Phillips

Blood (1991) 78 (3): 748–752.

https://doi.org/10.1182/blood.V78.3.748.748

Published: 1991

Journal Articles

Leukemia of non-T lineage natural killer cells

W Sheridan, EF Winton, WC Chan, DS Gordon, WR Vogler, C Phillips, KF Bongiovanni, TA Waldmann

Blood (1988) 72 (5): 1701–1707.

https://doi.org/10.1182/blood.V72.5.1701.1701

Published: 1988

NARROW

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

A Novel Aggressive NK Cell Leukemia Cell Line and Mouse Model for Evaluation of Therapeutic Candidates

The Combinatorial Activity of Eftozanermin (ABBV-621), a Novel and Potent TRAIL Receptor Agonist Fusion Protein, in Pre-Clinical Models of Hematologic Malignancies

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis

Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models

Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors

Inhibition of Cyclin Dependent Kinase 9 Synergistically Enhanced Venetoclax Activity in Mantle Cell Lymphoma Cells

Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

The Synergistic Effect of Venetoclax Combined with a CDK9 Inhibitor in Primary Diffuse Large B Cell Lymphoma and Follicular Lymphoma Cells

Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study

Leukemia of non-T lineage natural killer cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only